Blood, 1 November 2007, Vol. 110, No. 9, pp. 3387-3390.
Prepublished online as a Blood First Edition Paper on July 25, 2007; DOI 10.1182/blood-2007-03-082511.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Brief Report
Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6
Anja Mottok1,
Christoph Renné1,
Klaus Willenbrock1,
Martin-Leo Hansmann1, and
Andreas Bräuninger1
1 Senckenberg Institute of Pathology, University of Frankfurt, Frankfurt, Germany
Aberrant activities of JAK/STAT signaling pathways have been observed in several hematologic malignancies. Here, we show high expression of JAK2 in the tumor cells of lymphocyte-predominant Hodgkin lymphoma in 85% of cases and activation of JAK2 in 39% of cases. STAT6, which is a target of JAK2, was activated in 50% of the cases. SOCS1 controls JAK2 activity and degradation. Mutations in SOCS1 of either somatic or germ-line origin were observed in micromanipulated tumor cells of 50% of cases. Most mutations truncated SOCS1 or caused replacement of amino acids in functional important regions. Activating mutations in exon 12 of JAK2, which are frequent in myeloproliferative diseases, were not observed. In lymphocyte-predominant Hodgkin lymphoma SOCS1 function may thus be frequently impaired by mutations, and this may contribute to high JAK2 expression and activation of the JAK2/STAT6 pathway.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
|
|
